iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by Stonepine Capital Management LLC

Stonepine Capital Management LLC raised its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 266.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 110,000 shares of the company's stock after acquiring an additional 80,000 shares during the quarter. Stonepine Capital Management LLC owned approximately 0.30% of iTeos Therapeutics worth $845,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ITOS. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of iTeos Therapeutics during the 4th quarter worth $42,000. Virtus ETF Advisers LLC lifted its holdings in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after buying an additional 3,293 shares during the last quarter. Forefront Analytics LLC purchased a new stake in iTeos Therapeutics during the 4th quarter worth about $85,000. Graham Capital Management L.P. acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth about $85,000. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of iTeos Therapeutics in the 4th quarter valued at about $96,000. Institutional investors and hedge funds own 97.16% of the company's stock.

Analyst Upgrades and Downgrades

ITOS has been the topic of several research analyst reports. Leerink Partnrs lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Piper Sandler reissued an "overweight" rating and set a $12.00 price objective (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Wells Fargo & Company restated an "overweight" rating and issued a $13.00 target price (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, iTeos Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $17.86.

iTeos Therapeutics Stock Performance

NASDAQ ITOS traded up $0.03 on Friday, reaching $8.72. The stock had a trading volume of 290,106 shares, compared to its average volume of 567,190. The stock has a market cap of $333.56 million, a P/E ratio of -2.77 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.13. The business's 50-day moving average price is $6.70 and its 200 day moving average price is $7.41.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14. On average, sell-side analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Insider Buying and Selling at iTeos Therapeutics

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now directly owns 3,452,797 shares of the company's stock, valued at $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the transaction, the insider now owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is currently owned by company insiders.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.